Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.75 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.72 |
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358677 | 1.00 | ADORA3 (0.77) | ADORA3ADORA2AADORA2BNT5ECYP1A2 | |
| SCHEMBL5351524 | 0.89 | ADORA2A (0.77) | ADORA3ADORA2AADORA2BNT5ECYP1A2 | |
| SCHEMBL5351501 | 0.89 | ADORA2A (0.77) | ADORA3ADORA2AADORA2BNT5ECYP1A2 | |
| SCHEMBL5350420 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL5350425 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL5355770 | 0.87 | ADORA3 (0.76) | ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL5355789 | 0.87 | ADORA3 (0.76) | ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL19843951 | 0.85 | ADORA2A (0.81) | ADORA3ADORA2AADORA2BNT5ECYP1A2 | |
| SCHEMBL5360523 | 0.85 | ADORA3 (0.79) | ADORA3ADORA2AADORA2B | |
| SCHEMBL5360515 | 0.85 | ADORA3 (0.79) | ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7084127-B2 | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2006-08-01 | — | — | US | disclosed |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2004-07-08 | — | — | US | disclosed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | disclosed |
| EP-1368365-A2 | C2,5'-DISUBSTITUTED AND N6,C2,5'-TRISUBSTITUTED ADENOSINE DERIVATIVES AND THEIR DIFFERENT USES | Universiteit Leiden (NL) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002070532-A2 | C2,5'-DISUBSTITUTED AND N6,C2,5'-TRISUBSTITUTED ADENOSINE DERIVATIVES AND THEIR DIFFERENT USES | UNIVERSITEIT LEIDEN (NL) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA2B 4/4885 |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.